v3.25.4
FAIR VALUE MEASUREMENTS (Tables)
12 Months Ended
Dec. 31, 2025
Fair Value Disclosures [Abstract]  
Schedule of Assets and Liabilities Measured on a Recurring Basis
The following represents assets measured at fair value on a recurring basis by the Company (in thousands):
December 31, 2025Fair ValueLevel 1Level 2Level 3
Assets:
Money market funds$15,286 $15,286 $— $— 
Investment in iECURE744 — — 744 
Imugene Marketable Securities4,762 4,762 — — 
$20,792 $20,048 $— $744 
Liabilities:
Final payment fee$208 $— $208 $— 
Warrant liability15,695 — — 15,695 
$15,903 $— $208 $15,695 
December 31, 2024Fair ValueLevel 1Level 2Level 3
Assets:
Money market funds$14,687 $14,687 $— $— 
Investment in iECURE3,206 — — 3,206 
Imugene marketable securities413 413 — — 
Assets held for sale169 — — 169 
$18,475 $15,100 $— $3,375 
Liabilities:
Final payment fee$194 $— $194 $— 
Warrant liability2,796 — — 2,796 
$2,990 $— $194 $2,796 
Summary of Financial Assets Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs
The following represents a reconciliation of assets measured and carried at fair value on a recurring basis with the use of significant unobservable inputs (Level 3) for the year ended December 31, 2025 (in thousands). The warrant reconciliation is disclosed in Note 13, Warrants:
Investment in iECUREAssets held for sale
Balance December 31, 2024$3,206 $169 
Loss from changes in fair value included in earnings(2,462)(2)
Additions— — 
Assets sold— (21)
Write-offs— (146)
Balance December 31, 2025$744 $—